baber/WOPTO huggingface dataset:
Patent MX-2020003552-A (MX)
Inventor: JIANG YUTONG
IPC: C07D471/04
Filed: 2018-10-10
Abstract: En la presente se proporcionan compuestos de Fórmula I a IV y sales farmacéuticamente aceptables de estos que se exhiben reorganizados durante la inhibición de la quinasa por transfección (RET). En particular, se proporcionan en la presente nuevas formas cristalinas de 4-(6-(4-((6-metoxipiridin- 3-il)metil)piperazin-1-il)piridin-3-il)-6-(1-metil-1H-pirazol-4-i l)pirazolo[1,5-a]piridin-3-carbonitrilo (Fórmula I), 6 (2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)- 3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-l)pirazolo[1,5-a]pir idin-3-carbonitrilo (Fórmula II), 6-(2-hidroxi-2-metilpropoxi)-4-( 6-(6-(6-metoxnicotinoil)- 3,6-diazabiciclo[3.1.1]heptan-3-il)pirid in-3-il)pirazolo[1,5-a]piridin-3-carbonitrilo (Fórmula III), 6-(2-hidroxi-2- metilpropoxi)-4-(6-(4-hidroxi-4-(piridin-2-ilmetil )piperidin-1-il)piridin-3-il)pirazolo[1,5-a]piridin-3-carbonitril o (Fórmula IV), y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que comprenden los compuestos, procesos para elaborar los compuestos y el uso de los compuestos en terapia. Más particularmente, la solicitud se refiere a nuevas formas cristalinas de Fórmula I a IV y sales farmacéuticamente aceptables de estas útiles en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de quinasa RET, incluidas enfermedades y trastornos asociados con RET.
Patent MX-2020004505-A (MX)
Inventor: FARMER DOUGLAS K
IPC: D06N3/14
Filed: 2018-10-30
Abstract: Se proporcionan métodos para mejorar las funcionalidades de moldeo y/o soporte localizados, retención de la forma, comodidad y/o permanencia de la vestimenta y otros artículos de tela mediante la aplicación de una dispersión acuosa de poliuretano a una intensidad seleccionada y/o en una o más ubicaciones seleccionadas de la vestimenta u otros artículos de tela. Además, se proporcionan vestimenta y otros artículos de tela con funcionalidades mejoradas de moldeo y/o soporte localizados, retención de la forma y/o permanencia preparados de acuerdo con estos métodos.
Patent MX-2020004801-A (MX)
Inventor: SEAMAN JONATHAN
IPC: C07K19/00
Filed: 2018-11-08
Abstract: En la presente se proporcionan proteínas de fusión biespecíficas y métodos de uso de las proteínas de fusión biespecíficas para tratar el cáncer.
Patent MX-2020007303-A (MX)
Title: Bag storage system with dry biological samples for dna extraction.
Inventor: OCAMPO ACOSTA Gilberto Alejandro
IPC: B01L3/00
Filed: 2020-03-18
Abstract: The present invention relates to a dry biological tissue bag storage system, easy to visualize for efficient handling and location of samples. It consists of a front and a back sheet of any organic, synthetic, or process material, transparent, flexible, and strong enough to withstand routine use. Also, it includes a plurality of guard compartments, defined by margins containing bags with dry biological tissue and an opening for manipulating said bag. Further, it has a fixing means along one edge with at least three perforations for fastening to ring binders expected to streamline storage, inventory management, and optimizing space for distributing large numbers of biological samples.
Patent MX-2020012071-A (MX)
Title: Deblocking of implicit transform unit boundaries.
Inventor: SJÖBERG RICKARD
IPC: H04N19/119
Filed: 2019-05-14
Abstract: In one aspect there is disclosed a method of applying deblocking on implicit vertical TU boundaries when the CU width is larger than the maximum TU width and applying deblocking on implicit horizontal TU boundaries when the CU height is larger than the maximum TU height. Some exemplary embodiments include HEVC deblocking and deblocking using longer filters.
Patent MX-2021000403-A (MX)
Title: Composition of fused tricyclic î³-amino acid derivative and preparation therefor.
Inventor: YAN PANGKE
IPC: A61P29/00
Filed: 2019-07-12
Abstract: Disclosed are a pharmaceutical composition of a fused tricyclic Î³-amino acid derivative and the use thereof. The pharmaceutical composition comprises: (i) the structure as shown in formula (I) or a pharmaceutically acceptable salt thereof, as an active substance, wherein the weight percentage is 1%-45%; (ii) optionally one or more fillers, wherein the weight percentage is 50%-95%; and (iii) optionally one or more lubricants, wherein the weight percentage is 0.1%-5.5%. The sum of the weight percentages of all components is 100%. The structure of the pharmaceutically acceptable salt of the structure as shown in formula (I) is as shown in formula (I-A).
Patent MX-2021001191-A (MX)
Title: Utility vehicle with collapsible rear cab frame.
Inventor: GOFFMAN DANIEL L
IPC: B62D23/00
Filed: 2018-01-12
Abstract: A utility vehicle (2) includes front and rear ground-engaging members (6, 10) configured to contact a ground surface (G), a drive train assembly operably coupled to the ground-engaging members, and a frame (20) supported by the ground-engaging members and extending along a longitudinal axis of the utility vehicle. The utility vehicle also includes a rear cargo bed assembly (250) supported by the frame and extending over a portion of the rear ground-engaging member. The rear cargo bed assembly has a rear platform (300) with at least a first seating position. Additionally, the utility vehicle includes a rear cab frame assembly (500) with an upright position and a collapsed position. The vehicle has a first height (h1) from the ground surface when the rear cab frame is in the upright position and a second height (h2) from the ground surface less than the first height when the rear cab frame is in the collapsed position. The second height is 72-84 inches (182.8-213.36 cm).
Patent MX-2021003072-A (MX)
Title: Methods and compositions for enhanced oil recovery.
Inventor: TOIVONEN SUSANNA
IPC: C09K8/68
Filed: 2019-09-17
Abstract: The present embodiments generally relate to methods and compositions comprising one or more polymers which gradually increase in charge, thereby providing for an increase in viscosity in an aqueous solution or aqueous composition, such as when present in a desired aqueous environment. Use of such compositions and methods comprising one or more polymers which gradually increase in charge, thereby providing for an increase in viscosity in an aqueous solution or aqueous composition during enhanced oil recovery may result in an increase in oil production relative to methods and/or compositions which do not comprise one or more polymers which gradually increase in charge, thereby providing for an increase in viscosity in an aqueous solution or aqueous composition.
Patent MX-2021003500-A (MX)
Title: Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist.
Inventor: CROSIGNANI STEFANO
IPC: A61K31/7076
Filed: 2019-09-27
Abstract: The present invention relates to the use of an inhibitor of an ENT family transporter for the treatment of cancer. The invention further relates to the combined use of such inhibitor of an ENT family transporter with an adenosine receptor antagonist, for the treatment of cancer. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination.
Patent MX-2021004174-A (MX)
Title: System and method for removing uremic toxins from a patient's body.
Inventor: YAGER PAUL
IPC: C12N11/04
Filed: 2019-10-14
Abstract: Compositions and method for reducing the concentration of uremic toxins in the body of a patient suffering from some degree of kidney failure are disclosed. The methods can be used to delay the need for conventional dialysis treatment or as an adjunct therapy to reduce the frequency of dialysis sessions, and in some instances, as an alternative to such dialysis sessions.
Patent MX-2021007744-A (MX)
Title: Domperidone compositions and methods for treating depression.
Inventor: CHASE THOMAS N
IPC: A61K31/381
Filed: 2019-12-12
Abstract: The present invention describes the combination of domperidone with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
Patent MX-2021010255-A (MX)
Title: Fragile x mental retardation protein interfering oligonucleotides and methods of using same.
Inventor: VITI FRANCESCA
IPC: A61K31/7125
Filed: 2020-02-26
Abstract: Disclosed herein are antisense oligonucleotide sequences against fragile X mental retardation protein (FMRP) and methods of using the same for treating bowel diseases such as colorectal cancer and inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), associated with elevated activity or expression of FMRP. Also disclosed are pharmaceutical compositions containing an FMRP antisense oligonucleotide useful for treating a bowel disease and manufacture of medicaments containing a disclosed FMRP antisense oligonucleotide to be used in treating a bowel disease.
Patent MX-2021014318-A (MX)
Title: Facilities for financial instruments based on event happenings.
Inventor: LUTNICK HOWARD W
IPC: G06Q40/04
Filed: 2016-08-15
Abstract: Various embodiments of trading in financial instruments are given. In some embodiments, a trading venue may allow trading in futures contacts that relate to the outcome of competitions, such as sporting events, television competitions, and so on.
Patent MX-2022000956-A (MX)
Title: 1-(6-(methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway diseases.
Inventor: ROTH GERALD JUERGEN
IPC: A61K31/407
Filed: 2020-07-21
Abstract: The present invention relates to 1-(6-(methoxy)pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IPF) or systemic sclerosis (SSc). The present description discloses exemplary compounds (e.g. pages 50 to 65; examples 1.1 to 1.31) as well as relevant biological data thereof (e.g. pages 14 to 21, tables 1 to 9). An exemplary compound is e.g. N-(4-(7-acetyl-2,7- diazaspiro[3.5]nonan-2-yl)benzyl)-1-(6-((6-(trifluoromethyl)pyr idin-3- yl)methoxy)pyridazin-3-yl)cyclopropane-1-carboxamide (example 1.1).
Patent MX-2022001810-A (MX)
Title: 600mpa grade non-oriented electrical steel sheet and manufacturing method thereof.
Inventor: LI JUN
IPC: C22C38/02
Filed: 2020-08-26
Abstract: Provided is a 600MPa grade non-oriented electrical steel sheet with excellent magnetic properties, the mass percentages of chemical elements are: 0<Câ¤0.0035%; 2.0-3.5% of Si; 0.4-1.2% of Mn; 0.03-0.2% of P; 0.4-2.0% of Al; the residual is Fe and other unavoidable impurities. The manufacturing method of the electrical steel sheet includes the steps: (1) converter smelting, RH refining and casting; (2) hot rolling; (3) normalization; (4) cold rolling; (5) continuous annealing; (6) insulation coating to obtain the finished non-oriented electrical steel sheet.
Patent MX-2022003593-A (MX)
Title: Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions.
Inventor: YEAGER JAMES L
IPC: A61K31/519
Filed: 2020-05-12
Abstract: Various methods of treating single ventricle heart disease SVHD patients, including patients who have undergone Fontan surgery (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions. The methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle. In addition, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI. IThe methods of the present invention further include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output. The methods of the present invention further include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is at least 6 years old, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO<sub>2</sub>; (d) work rate at VAT; (e) VE/VCO2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.
Patent MX-2022005907-A (MX)
Title: Method and apparatus for acquiring data.
Inventor: SONG WEI
IPC: G06F16/9535
Filed: 2020-10-07
Abstract: A method for acquiring data. The method comprises: a first device generating a first message comprising a first condition and a first period, wherein the first condition corresponds to the first period; and the first device sending the first message to a second device, so that the second device reports data to the first device according to the first period when the first condition is satisfied. It can be seen therefrom that a period of a second device reporting data to a first device is a period determined according to a condition issued by the first device, which is conducive to the reduction of a device burden and the improvement of device performance.
Patent MX-2022006770-A (MX)
Title: Bendamustine solid dispersions and continuous infusion.
Inventor: VOUDOURIS VASILIOS
IPC: A61K9/14
Filed: 2016-08-30
Abstract: Provided herein are pharmaceutical compositions comprising nitrogen mustard, for example bendamustine hydrochloride, solid dispersions substantially free of degradants. Also provided are methods of producing and administering nitrogen mustards and in particular bendamustine hydrochloride solid dispersions substantially free of degradants. The pharmaceutical compositions can be used for any disease that is sensitive to treatment with bendamustine hydrochloride, such as neoplastic diseases.
Patent MX-2022007557-A (MX)
Title: Oral cannabinoid formulations.
Inventor: SILCOCK ALAN
IPC: A61K9/08
Filed: 2020-12-18
Abstract: The present invention relates to a cannabinoid containing oral solution. Preferably the cannabinoid is cannabidiol (CBD), cannabidivarin (CBDV) or cannabidiol-C4 (CBD-C4). More preferably the CBD, CBDV or CBD-C4 is present at a concentration of between 25 and 75 mg/ml. More preferably still the CBD, CBDV or CBD-C4 is present at a concentration of 50 mg/ml. In a further embodiment the oral solution is formulated with one or more edible oils. Preferably the edible oil is sesame oil. It is a preferred embodiment of the invention that the oral formulation comprises a low concentration of ethanol.
Patent MX-2022009975-A (MX)
Title: Set of biomarkers for the diagnosis of brugada syndrome.
Inventor: PAPPONE CARLO
IPC: C12Q1/6883
Filed: 2021-02-11
Abstract: The present invention relates to a specific set of circulating biomarkers and related methods and kits for the diagnosis of Brugada Syndrome in a human being.
Patent MX-2022014922-A (MX)
Title: Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates.
Inventor: HUNT HAZEL
IPC: A61K31/4745
Filed: 2021-05-26
Abstract: Relacorilant is useful in the treatment of cancer and hypercortisolism. Many drugs useful in treating cancer or hypercortisolism are metabolized by CYP2C8 enzymes. The effects of concomitant administration of relacorilant and a CYP2C8 substrate are disclosed herein. Relacorilant potently inhibited CYP2C8 in an <i>in vitro</i> test, indicating that co-administration of relacorilant and a CYP2C8 substrate would be expected to increase the CYP2C8 substrate plasma exposure more than five-fold <i>in vivo</i>. Significant reductions in CYP2C8 substrate doses would be expected to be required when administered with relacorilant. Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of CYP2C8 substrates such as pioglitazone, rosiglitazone, and enzalutamide. Relacorilant and unmodified doses of enzalutamide may be co-administered to treat cancer, e.g., prostate cancer. Relacorilant and unmodified doses of pioglitazone or rosiglitazone may be co-administered to treat cancer or hypercortisolism.Relacorilant is useful in the treatment of cancer and hypercortisolism. Many drugs useful in treating cancer or hypercortisolism are metabolized by CYP2C8 enzymes. The effects of concomitant administration of relacorilant and a CYP2C8 substrate are disclosed herein. Relacorilant potently inhibited CYP2C8 in an <i>in vitro</i> test, indicating that co-administration of relacorilant and a CYP2C8 substrate would be expected to increase the CYP2C8 substrate plasma exposure more than five-fold <i>in vivo</i>. Significant reductions in CYP2C8 substrate doses would be expected to be required when administered with relacorilant. Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of CYP2C8 substrates such as pioglitazone, rosiglitazone, and enzalutamide. Relacorilant and unmodified doses of enzalutamide may be co-administered to treat cancer, e.g., prostate cancer. Relacorilant and unmodified doses of pioglitazone or rosiglitazone may be co-administered to treat cancer or hypercortisolism. Provided herein are compositions and methods that can be utilized to ameliorate, treat, or at least partially eliminate diseases and conditions that can arise from genomic mutations. Subject compositions and methods can be used to edit RNA to ameliorate, treat, or at least partially eliminate the disease and conditions in a subject.
Patent MX-2023000343-A (MX)
Title: Packet loss concealment.
Inventor: MUNDT HARALD
IPC: G10L19/005
Filed: 2021-07-07
Abstract: Described are methods of processing an audio signal for packet loss concealment. The audio signal comprises a sequence of frames, each frame containing representations of a plurality of audio channels and reconstruction parameters for upmixing the plurality of audio channels to a predetermined channel format. One method includes: receiving the audio signal; and generating a reconstructed audio signal in the predefined channel format based on the received audio signal. Generating the reconstructed audio signal comprises: determining whether at least one frame of the audio signal has been lost; and if a number of consecutively lost frames exceeds a first threshold, fading the reconstructed audio signal to a predefined spatial configuration. Also described is a method of encoding an audio signal. Yet further described are apparatus for carrying out the methods, as well as corresponding programs and computer-readable storage media.
Patent MX-PA00004184-A (MX)
Title: Distribution bars protected against contacts.
Inventor: FABRIZIO FABRIZI
IPC: H02G5/04
Filed: 2000-04-28
Abstract: The present invention relates to finger-test safety electrical-current distribution bars. In particular, the present invention relates to an electrical-current distribution bar (1) comprising at least one strip (2, 2') which is a conductor of electrical energy, characterized in that it comprises, on at least one edge (7, 7', 8, 8') of the at least one strip (2, 2'), a profiled section (3a, 3b) made of insulating material such as not to permit frontal contact with the edge of the strip.
Patent MX-PA01002500-A (MX)
Title: Method and apparatus for lateral casing window cutting using hydrajetting.
Inventor: GARY T KEENE
IPC: E21B29/06
Filed: 2001-03-09
Abstract: A method and apparatus using hydrajetting of fluid to cut a lateral casing window for drilling a side track. The apparatus comprises a J-sub having a J-slot there in which guides movement of a jetting nozzle such that a window may be abrasively jetted in well casing in the general shape of the J-slot. In an alternate embodiment, a hydraulically activated actuator sub is used to operate the J-sub. The actuator sub is activated by alternately pressurizing and depressurizing the actuator sub to apply longitudinal movement and torque to the J-sub.
Patent MX-PA01003156-A (MX)
Title: Proteinic drug delivery system using membrane mimetics.
Inventor: MODI PANKAJ
IPC: A61K45/00
Filed: 1999-09-23
Abstract: A mixed liposome pharmaceutical formulation with multilamellar vesicles, comprises a proteinic pharmaceutical agent, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt. /wt.%, at least one membrane-mimetic amphiphile and at least one phospholipid. The amount of each membrane mimetic amphiphile and phospholipid is present 1 to 10 wt./wt.% of the total formulation, and the total concentration of membrane mimetic amphiphiles and phospholipids is less than 50 wt. /wt.% of the formulation. A process for preparing the formulation is described.
Patent MX-PA01005337-A (MX)
Title: Scratch resistant discontinuous acoustical surface coating.
Inventor: KENNETEH G CALDWELL
IPC: C09D5/02
Filed: 2001-05-28
Abstract: The present invention provides for both a composition and method for producing a scratch resistant coating applied to an acoustical panel. The coating primarily comprises binder, filler and mica and is typically applied as a spray. The coating can be characterized as a discontinuous film, whereby sound can pass through the coating to the panel for attenuating sound. The coating is thus enabled to provide a finish and color without compromising the acoustical performance of the substrate. The process primarily comprises combining and mixing the dry components of filler, binder and mica and then combining the same with water and mixing to create an aqueous mix that can be applied to the acoustical panel and dried.
Patent MX-PA02001694-A (MX)
Title: Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events.
Inventor: BERNWARD SCHOELKENS
IPC: A61K31/616
Filed: 2000-08-30
Abstract: The present invention relates to the use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; to a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; or to a combination product containing an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
Patent MX-PA02003371-A (MX)
Title: Shadow mask support frame for a cathode ray tube.
Inventor: JEAN-PIERRE REYAL
IPC: H04N5/65
Filed: 2002-04-02
Abstract: A shadow mask support frame for a colour cathode ray tube has a rectangular shape overall comprises two end uprights and two lateral uprights. The lateral uprights have a straight main part and two end parts each connected by at least one joining portion to an end upright. The lateral uprights have axes parallel to each other situated in a plane parallel to a reference plane of the frame. Each of the joining portions is in contact through a lateral face with an internal face of a substantially flat wall perpendicular to the reference plane of the frame, so that the end uprights of the frame are in abutment on the joining portions.